Selene opens Birmingham clinical research hub

Selene Clinical Research has opened a facility at Millennium Point in Birmingham and plans to employ up to 30 people there over the next three years.

The clinical research provider intends the Birmingham operation to become the first of six NHS-integrated research sites planned across the UK. Its work will include studies involving women and children, groups that have historically been underrepresented in parts of medical research.

The company plans to connect pharmaceutical and biotechnology sponsors with patients in the West Midlands while developing research delivery arrangements with local NHS providers. Recruitment is expected to cover clinical, research and operational roles.

Clinical trial operators compete partly on their ability to recruit suitable participants quickly and retain them throughout a study. Delays can extend development programmes and increase costs, particularly where trials need patients with specific conditions or demographic characteristics.

Location therefore plays a practical role in the research model. Birmingham gives Selene access to a large and diverse population alongside major hospitals, universities and an established life sciences base.

The emphasis on women and children also reflects longstanding concerns about representation in clinical research. Evidence generated from a narrow patient population can leave uncertainty about how treatments work across the wider group expected to use them.

Selene’s planned network is intended to expand access beyond a single city. Six NHS-integrated sites would give the company relationships with different healthcare providers and patient populations while allowing research sponsors to work through a common delivery organisation.

Replicating that model will require more than additional premises. Clinical research sites need qualified staff, consistent operating procedures, governance arrangements and working relationships with healthcare organisations. Sponsors also need confidence that study protocols will be delivered consistently across locations.

The Birmingham investment is relatively modest in employment terms compared with large industrial projects, but the roles are specialist and the facility is intended to attract clinical research activity from pharmaceutical and biotechnology companies.

That work can carry wider value for regional life sciences clusters. Research sites create demand for clinicians, trial managers and support services while helping local healthcare systems participate in commercial studies and giving patients access to research opportunities.

The first site will provide Selene with evidence on recruitment, operational performance and NHS integration before the company expands the model into five further locations. Its ability to reproduce those results will determine how quickly the proposed network develops.